Get the Stockscreener App
8.09
0.98%
-0.08
Actuate Therapeutics Inc stock is traded at $8.09, with a volume of 15,047.
It is down -0.98% in the last 24 hours and up +34.61% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$8.17
Open:
$8.2
24h Volume:
15,047
Relative Volume:
0.15
Market Cap:
$169.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.59%
1M Performance:
+34.61%
6M Performance:
-8.17%
1Y Performance:
+0.00%
1-Day Range:
$7.76
$8.41
1-Week Range:
$6.77
$8.43
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.30 | 149.64M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.34 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.20 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.01 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingInvestment Timing Strategy with Market Filters - Newser
Hillman Solutions Corp shares rise 3.41% intraday after Actuate Therapeutics announced a clinical trial collaboration with UPMC Hillman Cancer Center. - AInvest
Actuate Therapeutics to collaborate with Incyte Corporation on clinical trials - MarketScreener
Actuate Therapeutics To Collaborate with Incyte Corporation - GlobeNewswire
Risk adjusted return profile for Actuate Therapeutics Inc. analyzedWatchlist Summary for Active Day Traders - Newser
Does Actuate Therapeutics Inc. fit your quant trading modelExit Strategy Guide With Risk Control Plan - Newser
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Candlestick Signal Suggests Reversal in Actuate Therapeutics Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
What drives Actuate Therapeutics Inc. stock priceBuild wealth faster with consistent investment plans - Jammu Links News
Actuate Therapeutics Inc. Stock Analysis and ForecastBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Actuate Therapeutics Inc. stockAchieve consistent profits with proven strategies - Jammu Links News
Is Actuate Therapeutics Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is it the right time to buy Actuate Therapeutics Inc. stockAchieve superior returns with professional insights - Jammu Links News
Is Actuate Therapeutics Inc. a good long term investmentCapitalize on fast-growing stocks today - Jammu Links News
What are analysts’ price targets for Actuate Therapeutics Inc. in the next 12 monthsSuperior portfolio returns - Jammu Links News
What catalysts could drive Actuate Therapeutics Inc. stock higher in 2025Invest confidently with real-time market updates - Jammu Links News
What MACD signals say about Actuate Therapeutics Inc.7-Day Equity Return Range Forecast Model - Newser
What are Actuate Therapeutics Inc. company’s key revenue driversInvest confidently with professional market insights - Jammu Links News
What is the risk reward ratio of investing in Actuate Therapeutics Inc. stock - Jammu Links News
How volatile is Actuate Therapeutics Inc. stock compared to the marketFree Buy/Sell Signal Notifications - Jammu Links News
What makes Actuate Therapeutics Inc. stock price move sharplyHigh-return market picks - Jammu Links News
How strong is Actuate Therapeutics Inc. company’s balance sheetCapitalize on strategic market trends - Jammu Links News
How does Actuate Therapeutics Inc. compare to its industry peersTriple-digit wealth increases - Jammu Links News
What the charts say about Actuate Therapeutics Inc. todayInvestment Timing Strategy with Market Filters - Newser
Tick level data insight on Actuate Therapeutics Inc. volatilityTrading Opportunities Forecast by AI Insight - Newser
LifeMD Appoints Shayna Webb Dray as COO - The Globe and Mail
Volatility clustering patterns for Actuate Therapeutics Inc.Free Intraday Trend Analysis for Fast Gains - Newser
Actuate Therapeutics Inc. Trading Near Value Zone — Recovery AheadWeekly Watchlist of High Movers Released - metal.it
How Actuate Therapeutics Inc. stock performs during market volatilitySmart Chart Forecasting with AI Algorithms - Newser
Can swing trading help recover from Actuate Therapeutics Inc. lossesFundamental + Technical Combined Watchlist - Newser
Why Actuate Therapeutics Inc. stock attracts strong analyst attentionFree Real Trader Watchlist of Hot Stocks - Newser
Actuate Therapeutics: Elraglusib Continues to Impress, FDA Type B Meeting on Horizon - AInvest
Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting - Seeking Alpha
Will Actuate Therapeutics Inc. stock split in the near futureSwing Entry Risk Mitigation with Chart Analysis - Newser
How many analysts rate Actuate Therapeutics Inc. as a “Buy”Retirement Planning Tips With Low Risk - Jammu Links News
Published on: 2025-07-28 19:11:05 - metal.it
Why is Actuate Therapeutics Inc. stock attracting strong analyst attentionMaximize your portfolio’s growth with expert tips - Jammu Links News
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.46%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):